Why these two knee injections solve different problems

'Which injection is right for my knee?' is one of the most common questions at a first consultation about ChondroFiller and Arthrosamid. The honest answer is that the question itself may need reframing — because these two treatments are not competing options for the same problem. They are designed for structurally different conditions in the knee, and the choice between them is determined by what imaging actually shows, not by how much pain a patient is experiencing.

ChondroFiller is a collagen scaffold injection aimed at a focal cartilage defect: a discrete, localised patch of damaged cartilage, typically affecting a defined area of the femoral condyle or tibial plateau. Arthrosamid is a permanent hydrogel injection designed to address widespread, diffuse knee osteoarthritis — deterioration spread across the joint as a whole rather than confined to a single lesion.

The practical implication is significant. Many patients with knee OA do not have a focal defect at all; their cartilage loss is global. Equally, a younger active patient with an isolated cartilage lesion may have entirely healthy surrounding joint surfaces. Symptom severity alone cannot distinguish these two presentations — only accurate structural diagnosis, through MRI or clinical assessment, can. That diagnosis is the starting point for any sensible treatment decision.

What ChondroFiller does inside the knee

ChondroFiller is an acellular collagen scaffold — a cell-free Type I collagen gel placed inside a focal cartilage defect under ultrasound guidance as an outpatient injection. Once introduced into the joint, the gel sets in situ, creating a structured matrix within the damaged area without the need for arthroscopic surgery.

The mechanism is acellular matrix-induced chondrogenesis. Rather than delivering cells directly, ChondroFiller provides a physical scaffold that recruits the patient's own progenitor cells — drawn from the surrounding synovium and subchondral bone — into the lesion site. An ex vivo osteochondral model recorded a 2.4-fold increase in DNA content within the scaffold by day 14, confirming active cellular migration into the collagen matrix.

The treatment targets Grade III–IV focal chondral lesions — areas of deep or full-thickness cartilage loss confined to a discrete zone of the joint surface — in knees where the surrounding cartilage remains relatively intact. In a cohort of 17 knee patients with a mean age of 31, Lysholm and IKDC scores improved significantly at 3, 6, and 12 months after treatment. A randomised study comparing ChondroFiller against microfracture confirmed significant IKDC gains and, on MRI, progressive maturation of the reconstructed cartilage area at 52 weeks with no adverse events reported in either group.

Where diffuse osteoarthritis is already established — with significant background joint-space narrowing spread across the joint — outcomes are poor and ChondroFiller is not appropriate. In that clinical picture, the relevant question shifts from focal scaffold repair to whole-joint symptom management, which is precisely the territory where Arthrosamid operates.

What Arthrosamid does inside the knee

Administered as a single 6 mL outpatient injection, Arthrosamid is a permanently integrated hydrogel comprising 97.5% water and 2.5% cross-linked polyacrylamide. Once placed into the knee joint cavity, the gel does not dissolve or reabsorb — over 10–14 days it integrates into the sub-synovial layer through synovial cell proliferation, forming a stable, vascularised sub-synovial cushion by 30–90 days. This process, described in the literature as a low-level macrophage-driven foreign body response, modifies pain signalling through the joint lining without touching the cartilage surface.

That last point is fundamental: Arthrosamid does not aim to repair or regenerate cartilage. Its clinical purpose is durable symptom modification in moderate-to-severe diffuse knee osteoarthritis — settings where the treatment goal is sustained pain reduction rather than structural restoration.

Permanence is something patients need to understand before consenting. The hydrogel, once integrated, is not reabsorbed and there is no planned re-injection cycle.

The outcome data cover two independent 5-year datasets. An open-label extension (n=27 completers) showed WOMAC pain improvement of −14.6 points at year 5; an RCT extension (NCT04045431; n=58 completers) confirmed −16.2 points at the same timepoint, with no serious device-related adverse events reported in either. WOMAC improvements across published series range from −15 to −21 points over 6 months to 3 years. In a retrospective comparison with corticosteroid and hyaluronic acid, iPAAG outperformed corticosteroid at 6 months; at 12 months, no statistically significant difference from HA was observed.

Which patients suit each treatment

Two broad patient profiles emerge from the clinical evidence — and the dividing line runs through the imaging report, not the pain score.

The ChondroFiller profile is a generally younger, active patient with a discrete, focal cartilage defect confined to one area of the joint surface, surrounded by otherwise healthy articular cartilage. Structural integrity of the surrounding tissue matters as much as the lesion itself, because the scaffold depends on that environment to support cell recruitment and stable integration. Where imaging reveals pre-existing diffuse osteoarthritis — joint-space narrowing spread across multiple compartments, regardless of how severe the symptoms feel — outcomes with ChondroFiller are poor and the approach is not appropriate.

The Arthrosamid profile sits at the opposite end of the OA spectrum: typically an older patient with moderate-to-severe diffuse knee osteoarthritis, broader joint involvement, and a priority of sustained pain relief rather than structural restoration. Real-world 24-month data from 314 knees identified the optimal responder as older, non-diabetic, lower Kellgren–Lawrence grade, and with bilateral OA. Importantly, at two years, 15.6% of patients — concentrated in those with more advanced disease — went on to total knee replacement, which underlines the importance of honest pre-treatment discussion about realistic expectations.

Age and OA severity on imaging are the primary stratifiers. Pain duration and symptom severity alone do not determine which — if either — treatment applies.

Some patients fall into an overlap zone: a focal lesion sitting against a background of early-to-moderate diffuse OA. Here the decision becomes considerably more nuanced, and detailed MRI cartilage characterisation — assessing surrounding cartilage health, subchondral bone integrity, and global joint architecture — is needed before any treatment pathway can be recommended. No head-to-head RCT has yet compared the two approaches, so imaging-guided clinical judgement remains central to patient selection.

That MRI picture is typically where a structured assessment begins.

What the clinical evidence shows and where it runs out

The two evidence bases differ in scale, follow-up length, and what they actually measure — and those differences matter when weighing a treatment decision.

ChondroFiller's published knee data, covered in detail earlier, is clinically encouraging. The meaningful IKDC and Lysholm gains seen across those studies are not trivial effect sizes. The honest limiting factor is statistical power: both the cohort study and the randomised comparison involve small patient numbers, which makes the findings persuasive rather than definitive. MRI maturation data at 52 weeks adds structural weight, but longer-term imaging follow-up — confirming whether the repaired tissue holds up over years rather than months — is not yet available in the published literature for the injectable delivery route specifically. That gap is worth naming plainly: the question of whether an ultrasound-guided injectable ChondroFiller scaffold produces durable structural preservation over three to five years remains open.

Arthrosamid's evidence base is substantially broader. The 24-month real-world PROMs cohort alone covers 314 knees, and two independent 5-year datasets confirm that the WOMAC pain improvements first seen at six months are maintained at year five without serious device-related events. That is a longer and larger follow-up record than most intra-articular therapies carry. What the evidence does not show — by design — is any cartilage repair. Every outcome measure tracks symptoms; structural imaging is not the primary endpoint in any of the published Arthrosamid trials.

Three evidence gaps stand out. No head-to-head randomised trial comparing ChondroFiller and Arthrosamid exists, so any direct comparison rests on cross-study inference rather than controlled data. For ChondroFiller as an injectable, published structural outcome data beyond 12 months in the knee is absent. For Arthrosamid, reassuring safety data now reaches five years, but the implications of a permanent non-biodegradable implant over one or two decades remain uncharacterised — acrylamide monomer leaching, though stated by manufacturers to be removed during production, represents a theoretical long-term concern that current follow-up periods cannot rule out.

Getting an accurate diagnosis before committing to either

The single imaging finding that separates the two pathways is whether cartilage loss is focal or diffuse. Everything else — symptom duration, pain score, activity demands — informs the picture, but that structural distinction on MRI is what makes the decision clinically actionable.

A structured assessment moves from symptom history and physical examination through to dedicated cartilage MRI, allowing the treating consultant to grade lesion extent, map OA distribution across joint compartments, and review subchondral bone integrity. At Lincolnshire Knee, onMRI™ AI-assisted cartilage characterisation supports that step by quantifying defect depth and T2 mapping signals alongside standard reporting. The consultant then weighs OA grade, lesion focality, patient age, activity level, and prior treatment history before any recommendation is made.

Not every patient will be a candidate for either injection. Where MRI reveals advanced diffuse OA across multiple compartments, the more useful conversation is often about osteotomy or arthroplasty planning rather than any injectable pathway — and identifying that early avoids directing someone toward a treatment unlikely to deliver lasting benefit.

The central argument running through this comparison holds at the assessment stage too: these are different tools built for structurally different problems, and reaching the right one depends on a clear picture of which problem is actually present.

Lincolnshire Knee is part of the MSK Doctors group and accepts patients without referral. Book an assessment at lincolnshireknee.co.uk.

1. [1] IMPLANTATION OF CHONDROFILLER LIQUID® AS A SCAFFOLD MATERIAL FOR THE TREATMENT OF CHONDRAL LESIONS OF THE KNEE JOINT. (2024). https://doi.org/10.5272/jimab.2024304.5936 https://doi.org/10.5272/jimab.2024304.5936
2. [2] Polyacrylamide hydrogel injections in knee osteoarthritis: A PROMs-based 24 month cohort study. (2025). https://doi.org/10.1016/j.jcot.2025.103136 https://doi.org/10.1016/j.jcot.2025.103136
3. [3] Development of an Ex Vivo Osteochondral Biomimetic Platform for Mechanistic Investigation of Cartilage Regeneration. (2025). https://doi.org/10.3390/ijms262311759 https://doi.org/10.3390/ijms262311759
4. [4] A prospective, open-label, clinical investigation of a single intra-articular polyacrylamide hydrogel injection in participants with knee osteoarthritis: a 5-year extension study. (2025). https://doi.org/10.1186/s13018-025-06526-0 https://doi.org/10.1186/s13018-025-06526-0
5. [5] Controlled, randomized multicenter study to compare compatibility and safety of ChondroFiller liquid with microfracturing of patients with focal cartilage defects of the knee joint. (2016). https://doi.org/10.5348/VNP05-2016-1-OA-1 https://doi.org/10.5348/VNP05-2016-1-OA-1
6. [6] Sustained symptom relief and safety over five years following a single intra-articular injection of 2.5% polyacrylamide hydrogel in patients with knee osteoarthritis. (2025). https://doi.org/10.55563/clinexprheumatol/bsper8 https://doi.org/10.55563/clinexprheumatol/bsper8
7. [7] Arthroscopic utilization of ChondroFiller gel for the treatment of hip articular cartilage defects: a cohort study with 12- to 60-month follow-up. (2021). https://doi.org/10.1093/jhps/hnab002 https://doi.org/10.1093/jhps/hnab002
8. [8] Influence of cartilage defects and a collagen gel on integrity of corresponding intact cartilage: a biomechanical in-vitro study. (2024). https://doi.org/10.1007/s00402-024-05530-z https://doi.org/10.1007/s00402-024-05530-z
9. [9] Comparative efficacy of polyacrylamide hydrogel versus hyaluronic acid and corticosteroids in knee osteoarthritis: A retrospective cohort study. (2025). https://doi.org/10.1097/MD.0000000000044655 https://doi.org/10.1097/MD.0000000000044655